Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6023010

Title:Transgenic non-human animals depleted in a mature lymphocytic cell-type
Inventors:Krimpenfort, Paulus Jacobus Angelinus; Amsterdam, Netherlands
Berns, Antonius Johannes Maria; Spaarndam, Netherlands
Summary:This invention introduces novel transgenic nonhuman mammals which are depleted in mature lymphocytic cells, methods and uses thereof. Described herein are transgenic mice having a phenotype characterized by the substantial depletion of a mature lymphocytic cell type otherwise naturally occurring in wild-type mice, and which results from a transgene encoding a lymphatic polypeptide variant which inhibits the formation of lymphocyte cells. Further disclosed are the means by which the phenotype is conferred in the transgenic mouse by a transgene contained in the precursor stem cell of the lymphocytic cell type which is depleted, such that the transgene comprises a DNA sequence encoding a lymphatic polypeptide variant which inhibits maturation of the lymphocytic cell type. Therapeutic and experimental applications are included.
Abstract:Transgenic mice having a phenotype characterized by the substantial depletion of a mature lymphocytic cell type otherwise naturally occurring in the species from which the transgenic mouse is derived. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the lymphocytic cell type which is depleted. The transgene comprised is a DNA sequence encoding a lymphatic polypeptide variant which inhibits maturation of the lymphocytic cell type.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6023010
Application Number:US1996000761765
Date Filed:05/12/1996
Date Published:08/02/2000
Assignee:GenPharm International Inc., Palo Alto, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/10/2020